The stock of Adc Therapeutics SA (NYSE:ADCT) last traded at $2.72, down -3.55% from the previous session.
ADCT stock price is now -33.83% away from the 50-day moving average and 2.43% away from the 200-day moving average. The market capitalization of the company currently stands at $261.75M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On March 28, 2024, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $11, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Azelby Robert, Director sold 6,995 shares of the company’s stock on Jun 17 ’24. The stock was sold for $20,216 at an average price of $2.89. Upon completion of the transaction, the Director now directly owns 53,005 shares in the company, valued at $0.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 17 ’24, Director BIZZARI JEAN-PIERRE sold 6,995 shares of the business’s stock. A total of $20,216 was realized by selling the stock at an average price of $2.89. This leaves the insider owning 79,502 shares of the company worth $0.22 million. A total of 20.15% of the company’s stock is owned by insiders.
During the past 12 months, Adc Therapeutics SA has had a low of $0.36 and a high of $6.04. The fifty day moving average price for ADCT is $4.0634 and a two-hundred day moving average price translates $2.66297 for the stock.
The latest earnings results from Adc Therapeutics SA (NYSE: ADCT) was released for 2024-03-31. The net profit margin was -330.17% and return on equity was -705.53% for ADCT. The company reported revenue of $18.05 million for the quarter, compared to $18.99 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -4.94 percent.
